Multiomic analysis of cytokines in immuno-oncology

References

• Zumkeller W, Schofi Eld PN. Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res. 1995;15:344–348.
   Web of Science ®Google Scholar
• Van der Meide PH, Schellekens H. Cytokines and the immune response. Biotherapy. 1996;8:243–249.
   PubMedGoogle Scholar
• Lucey DR, Clerici M, Shearrer GM. Type 1 and type 2 cytokine dysregulation in human infectious neoplastic and inflammatory diseases. Clin Microbiol Rev. 1996;9:532–552.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, McDermott DF. Interferon, interleukin-2, and other cytokines. Hematol Oncol Clin North Am. 2014;28(3):571–583.
   PubMed Web of Science ®Google Scholar
• Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23(Suppl 8):viii6–9.
   PubMed Web of Science ®Google Scholar
• Bai L, Mao GP, Cao CP. Effects of inflammatory cytokines on the recurrence of liver cancer after an apparently curative operation. J Dig Dis. 2007;8:154–159.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570.
   PubMed Web of Science ®Google Scholar
• Jurišić V, Vuletić A, Mirjačić Martinović K, et al. The role of NK cells in cancer. In: Rezaei N, editor. Cancer immunology, a translational medicine context. 2nd ed. Springer International Publishing; 2020. p. 133–146. DOI:10.1007/978-3-030-30845-2_9
   Google Scholar
• Trotta R, Dal Col J, Yu J, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol. 2008;181:3784–3792.
   PubMed Web of Science ®Google Scholar
• Mueller TD, Zhang JL, Sebald W, et al. Structure, binding, and antagonists in the IL-4/IL-13 receptor system. Biochim Biophys Acta. 2002;1592:237–250.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol. 2006;6:595–601.
   PubMed Web of Science ®Google Scholar
• Li Z, Chen L, Qin Z. Paradoxical roles of IL-4 in tumor immunity. Cell Mol Immunol. 2009;6(6):415–422.
   PubMed Web of Science ®Google Scholar
• Zaidi MR, Merlino G. The two faces of interferon-? In cancer. Clin Cancer Res. 2011;17(19):1–7.
   Web of Science ®Google Scholar
• Foster JR. The functions of cytokines and their uses in toxicology. Int J Exp Pathol. 2001;82:171–192.
   PubMed Web of Science ®Google Scholar
• Naylor MS, Stamp GWH, Foulkes WD, et al. Tumor necrosis factor and its receptors in human ovarian cancer: potential role in disease progression. J Clin Invest. 1997;57:141–146.
   Google Scholar
• Jewett A, Tseng HC. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer. 2011;2:443–457.
   PubMed Web of Science ®Google Scholar
• Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors. 2010;36:274–288.
   PubMed Web of Science ®Google Scholar
• Jurisić V, Bogdanovic G, Srdic T, et al. Modulation of TNF-alpha activity in tumor PC cells using anti-CD45 and anti-CD95 monoclonal antibodies. Cancer Lett. 2004 8;214(1):55–61.
   PubMed Web of Science ®Google Scholar
• Macarthur M, Hold GL, El-Omar EM. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. 2004;286:G515–20.
   PubMed Web of Science ®Google Scholar
• Chew V, Toh VC, Abastado JP. Immune microenvironment in tumor progression: characteristics and challenges for therapy. J Oncol. 2012;2012:1–10.
   Google Scholar
• Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001;61:3541–3543.
   PubMed Web of Science ®Google Scholar
• Hefler LA, Grimm C, Ackermann S, et al. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer. Cancer Res. 2003;63:3066–3068.
   PubMed Web of Science ®Google Scholar
• Chen M, Chen LM, Lin CY, et al. The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. Biochim Biophys Acta. 2008;1783:896–903.
   PubMed Web of Science ®Google Scholar
• Rath T, Billmeier U, Waldner MJ, et al. From physiology to disease and targeted therapy: interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol. 2015;89:541–554.
   PubMed Web of Science ®Google Scholar
• Voorzanger N, Touitou R, Garcia E, et al. Interleukin (IL)-10 and IL-6 are produced in vivo by non-hodgkins lymphoma cells and act as cooperative growth factors. Cancer Res. 1996;56:5499–5505.
   PubMed Web of Science ®Google Scholar
• Konjević GM, Vuletić AM, Mirjačić Martinović KM, et al. The role of cytokines in the regulation of NK cells in the tumor environment. Cytokine. 2019;117:30–40.
   PubMed Web of Science ®Google Scholar
• Vuletić A, Jovanić I, Jurišić V, et al. IL-2 and IL-15 induced NKG2D, CD158a and CD158b expression on T, NKT- like and NK cell lymphocyte subsets from regional lymph nodes of melanoma patients. Pathol Oncol Res. 2020;26(1):223–231.
   PubMed Web of Science ®Google Scholar
• Leblay N, Maity R, Hasan F, et al. Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities. Front Oncol. 2020;10:636.
   PubMed Web of Science ®Google Scholar
• Prabhala RH, Pelluru D, Fulciniti M, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010;115:5385–5392.
   PubMed Web of Science ®Google Scholar
• Liu Z, Yuan X, Luo Y, et al. Evaluating the effects of immunosuppressants on human immunity using cytokine profiles of whole blood. Cytokine. 2009;45:141–147.
   PubMed Web of Science ®Google Scholar
• Mauer J, Denson JL, Brüning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol. 2015;36:92–101.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50.
   PubMed Web of Science ®Google Scholar
• Galon J, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res. 2007;67:1883–1886.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.
   PubMed Web of Science ®Google Scholar
• Majumdar MK, Thiede MA, Haynesworth SE, et al. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res. 2000;9(6):841–848.
   PubMedGoogle Scholar
• Lieksche GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1992;327:28–34.
   PubMedGoogle Scholar
• Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines–CXC and CC chemokines. Adv Immunol. 1994;55:97–179.
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 2011;11(9):597–606.
   PubMed Web of Science ®Google Scholar
• Hojo S, Koizumi K, Tsuneyama K, et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res. 2007;67(10):4725–4731.
   PubMed Web of Science ®Google Scholar
• Wendel M, Galani IE, Suri-Payer E, et al. Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands. Cancer Res. 2008;68(20):8437–8445.
   PubMed Web of Science ®Google Scholar
• Abrahamsson A, Rzepecka A, Dabrosin C. Equal pro-inflammatory profiles of CCLs, CXCLs, and matrix metalloproteinases in the extracellular microenvironment in vivo in human dense breast tissue and breast cancer. Front Immunol. 2018 16;8:1994.
   PubMed Web of Science ®Google Scholar
• Jones A, Fujiyama C, Blanche C, et al. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell lines. Clin Cancer Res. 2001 May;7(5):1263–1272.
   PubMed Web of Science ®Google Scholar
• Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342:1350–1358.
   PubMed Web of Science ®Google Scholar
• Paralkar VM, Vail AL, Grasser WA, et al. Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem. 1998;273:13760–13767.
   PubMed Web of Science ®Google Scholar
• Uribe-Herranz M, Kuguel SG, Casós K, et al. Characterization of putative regulatory isoforms of porcine tumor necrosis factor receptor 2 in endothelial cells. Xenotransplantation. 2020;11:e12635.
   Google Scholar
• Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984;312(5996):724–729.
   PubMed Web of Science ®Google Scholar
• Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002;27(1):19–26.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Bogdanovic G, Kojic V, et al. Effect of TNF-alpha on Raji cells at different cellular levels estimated by various methods. Ann Hematol. 2006;85(2):86–94.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Bumbasirevic V, Konjevic G, et al. TNF-alpha induces changes in LDH isotype profile following triggering of apoptosis in PBL of non-Hodgkin’s lymphomas. Ann Hematol. 2004;83(2):84–91.
   PubMed Web of Science ®Google Scholar
• Jurisić V, Plećić M, Colović N, et al. MUM-1 and bcl-2 positive primary diffuse large B cell non-hodgkin’s lymphoma of the colon. Arch Iran Med. 2016;19(4):297–299.
   PubMed Web of Science ®Google Scholar
• Nedwin GE, Naylor SL, Sakaguchi AY, et al. Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization. Nucleic Acids Res. 1985 11;13(17):6361–6373.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–1284.
   PubMed Web of Science ®Google Scholar
• Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res. 2003;9:2642–2650.
   PubMed Web of Science ®Google Scholar
• Abbass SA, Asa SL, Ezzat S. Altered expression of fibroblast growth factor receptors in human pituitary adenomas. J Clin Endocrinol Metab. 2001;82:1160–1166.
   Google Scholar
• Karamysheva AF, Shushanov SS, Adelaide J, et al. Expression of the FLT4/VEGFR3 receptor tyrosine kinase encoding gene in hepatic tumors. Int J Oncol. 1996;8:921–924.
   PubMed Web of Science ®Google Scholar
• François S, Usunier B, Forgue-Lafitte ME, et al. Mesenchymal stem cell administration attenuates colon cancer progression by modulating the immune component within the colorectal tumor microenvironment. Stem Cells Transl Med. 2018:19. DOI:10.1002/sctm.18-0117.
   Web of Science ®Google Scholar
• Larsen AK, Ouaret D, El Ouadrani K, et al. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Pharmacol Ther. 2011;131:80–90.
   PubMed Web of Science ®Google Scholar
• Dittrich A, Quaiser T, Khouri C, et al. Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling. Mol Biosyst. 2012;8:2119–2134.
   PubMedGoogle Scholar
• Ahn R, Sabourin V, Bolt AM, et al. The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression. Nat Commun. 2017;8:14638.
   PubMed Web of Science ®Google Scholar
• Johnston JA, Bacon CM, Finbloom DS, et al. Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci USA. 1995;92:8705–8709.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Srdic-Rajic T, Konjevic G, et al. TNF-α induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol. 2011;239:115–122.
   PubMed Web of Science ®Google Scholar
• Hartmann M, Parra LM, Ruschel A, et al. Inside-out regulation of ectodomain cleavage of cluster-of-differentiation44 (CD44) and of neuregulin-1 requires substrate dimerization. J Biol Chem. 2015;290:17041–17054.
   PubMed Web of Science ®Google Scholar
• Widlak P, Garrard WT. Discovery, regulation, and action of the major apoptotic nucleases DFF40/CAD and endonuclease G. J Cell Biochem. 2005;94(6):1078–1087.
   PubMed Web of Science ®Google Scholar
• Slee EA, Adrain C, Martin SJ. Executioner caspase-3, −6, and −7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem. 2001;276(10):7320–7326.
   PubMed Web of Science ®Google Scholar
• Rahimi N, Golde TE, Meyer RD. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res. 2009;69:2607–2614.
   PubMed Web of Science ®Google Scholar
• Ghedini GC, Ciravolo V, Tortoreto M, et al. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. J Cell Physiol. 2010;225:256–265.
   PubMed Web of Science ®Google Scholar
• Miller MA, Meyer AS, Beste MT, et al. ADAM-10 and −17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling. Proc Natl Acad Sci USA. 2013;110:E2074–83.
   PubMed Web of Science ®Google Scholar
• Salmon H, Franciszkiewicz K, Damotte D. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 2012 Mar;122(3):899–910.
   PubMed Web of Science ®Google Scholar
• Robles A, Harris C. Integration of multiple “OMIC” biomarkers: a precision medicine strategy for lung cancer. Lung Cancer. 2017May;107:50–58.
   PubMed Web of Science ®Google Scholar
• Barrera L, Montes-Servín E, Barrera A, et al. Cytokines profile determined by data mining analysis set into clusters non-small cell lung cancer patients according to prognosis. Ann Oncol. 2015;26:428–435.
   PubMed Web of Science ®Google Scholar
• Lyon DE, Cohen R, Chen H, et al. Relationship of systemic cytokine concentrations to cognitive function over two years in women with early stage breast cancer. J Neuroimmunol. 2016;301:74–82.
   PubMed Web of Science ®Google Scholar
• Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care. 2007;11:R49.
   PubMed Web of Science ®Google Scholar
• Nixon AB, Pang H, Starr MD, et al. Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). Clin Cancer Res. 2013;19:6957–6966.
   PubMed Web of Science ®Google Scholar
• Bachelot T, Ray-Coquard I, Menetrier-Caux C, et al. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer. 2003;88:1721–1726.
   PubMed Web of Science ®Google Scholar
• Corsini E, House RV. Evaluating cytokines in immunotoxicity testing. Methods Mol Biol. 2010;598:283–302.
   PubMedGoogle Scholar
• Corsini E, House RV. Evaluating Cytokines in Immunotoxicity Testing. In: DeWitt J, Rockwell C, Bowman C, editors. Immunotoxicity testing. Methods in molecular biology. Vol. 1803. New York (NY): Humana Press; 2018. DOI:10.1007/978-1-4939-8549-4_18
   Google Scholar
• Knight PR, Sreekumar A, Siddiqui J, et al. Development of a sensitive microarray immunoassay and comparison with standard enzyme-linked immunoassay for cytokine analysis. Shock. 2004;21:26–30.
   PubMed Web of Science ®Google Scholar
• Haack M, Pollmacher T, Mullington JM. Diurnal and sleep-wake dependent variations of soluble TNF- and IL-2 receptors in healthy volunteers. Brain Behav Immun. 2004;18:361–367.
   PubMed Web of Science ®Google Scholar
• Banks RE. Measurement of cytokines in clinical samples using immunoassays: problems and pitfalls. Crit Rev Clin Lab Sci. 2000;37:131–182.
   PubMed Web of Science ®Google Scholar
• Lum G, Gambino SR. A comparison of serum versus heparinized plasma for routine chemistry tests. Am.J.Clin.Pathol. 1974;61:108–113.
   PubMed Web of Science ®Google Scholar
• Riches P, Gooding R, Millar BC, et al. Influence of collection and separation of blood samples on plasma IL-1, IL-6 and TNF-alpha concentrations. J Immunol Methods. 1992;153:125–131.
   PubMed Web of Science ®Google Scholar
• Cannon JG, Van der Meer JW, Kwiatkowski D, et al. Interleukin-1 beta in human plasma: optimization of blood collection, plasma extraction, and radioimmunoassay methods. Lymphokine Res. 1988;7:457–467.
   PubMedGoogle Scholar
• Elsässer-Beile U, von Kleist S, Stähle W, et al. Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma. Cancer. 1993;71:231–236.
   PubMed Web of Science ®Google Scholar
• Haytaoglu G, Kuzu F, Arpaci D, et al. Correlation of vascular endothelial growth factor and vascular endothelial growth factor receptor-1 levels in serum and thyroid nodules with histopathological and radiological variables. J Lab Physicians. 2019;11(1):51–57.
   PubMed Web of Science ®Google Scholar
• Seiler W, Muller H, Hiemke C. Interleukin-6 in plasma collected with an indwelling cannula reflects local, not systemic, concentrations. Clin.Chem. 1994;40:1778–1779.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Terzic T, Colic S, et al. The concentration of TNF-alpha correlate with number of inflammatory cells and degree of vascularization in radicular cysts. Oral Dis. 2008;14(7):600–605.
   PubMed Web of Science ®Google Scholar
• Dabrosin C. Microdialysis – an in vivo technique for studies of growth factors in breast cancer. Front Biosci. 2005;10:1329–1335.
   PubMed Web of Science ®Google Scholar
• Mancuso F, Lage S, Rasero J, et al. Serum markers improve current prediction of metastasis development in early‐stage melanoma patients: a machine learning‐based study. Mol Oncol. 2020;2. DOI:10.1002/1878-0261.12732.
   Google Scholar
• Jurisić V, Colović M. Correlation of sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med Oncol. 2002;19(3):133–139.
   PubMed Web of Science ®Google Scholar
• Jurisic V, Terzic T, Pavlovic S, et al. Elevated TNF-alpha and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis. Pathol Res Pract. 2008;204(2):129–132.
   PubMed Web of Science ®Google Scholar
• Maeda Y, Takeuchi H, Matsuda S, et al. Clinical significance of preoperative serum concentrations of interleukin-6 as a prognostic marker in patients with esophageal cancer. Esophagus. 2020;17(3):279–288.
   PubMed Web of Science ®Google Scholar
• Sawada R, Arai Y, Sagawa Y, et al. High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer. Oncol Rep. 2019;42(5):2057–2064.
   PubMed Web of Science ®Google Scholar
• Kučera J, Strnadová K, Dvořánková B, et al. Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: pilot study. Oncol Rep. 2019;42(5):1793–1804.
   PubMed Web of Science ®Google Scholar
• Gaur P, Bhattacharya S, Kant S, et al. Association of inflammatory biomarkers with lung cancer in North Indian population. Afr Health Sci. 2019;19(2):2147–2155.
   PubMed Web of Science ®Google Scholar
• Nikolinakos PG, Altorki N, Yankelevitz D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res. 2010 15;70(6):2171–2179.
   PubMed Web of Science ®Google Scholar
• Bendrik C, Dabrosin C. Estradiol increases IL-8 secretion of normal human breast tissue and breast cancer in vivo. J Immunol. 2009;182(1):371–378.
   PubMed Web of Science ®Google Scholar
• Schuerwegh AJ, de Clerck LS, Bridts CH, et al. Comparison of intracellular cytokine production with extracellular cytokine levels using two flow cytometric techniques. Cytometry B Clin Cytom. 2003;55(1):52–58.
   PubMedGoogle Scholar
• Vuletić A, Jovanić I, Jurišić V, et al. Decreased interferon γ production in CD3+ and CD3- CD56+ lymphocyte subsets in metastatic regional lymph nodes of melanoma patients. Pathol Oncol Res. 2015;21(4):1109–1114.
   PubMed Web of Science ®Google Scholar
• Hagiwara E, Abbasi F, Mor G, et al. Phenotype and frequency of cells secreting IL-2, IL-4, IL-6, IL-10, IFN and TNF-α in human peripheral blood. Cytokine. 1995;7(8):815–822.
   PubMed Web of Science ®Google Scholar
• Bendall SC, Nolan GP. From single cells to deep phenotypes in cancer. Nature Biotechnol. 2012;30(7):639–647.
   PubMed Web of Science ®Google Scholar
• Schmittel A, Keilholz U, Scheibenbogen C. Evaluation of the interferon-γ ELISpot-assay for quantification of peptide specific T lymphocytes from peripheral blood. J Immunol Methods. 1997;210(2):167–174.
   PubMed Web of Science ®Google Scholar
• Duncan MW, Nedelkov D, Walsh R, et al. Applications of MALDI mass spectrometry in clinical chemistry. Clin Chem. 2016;62(1):134–143.
   PubMed Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422(6928):198–207.
   PubMed Web of Science ®Google Scholar
• Kellar KL, Mahmutovic AJ, Bandyopadhyay K. Multiplexed microsphere-based flow cytometric immunoassays. Curr Protoc Cytom. 2006;Chapter 13:Unit13.1.
   PubMedGoogle Scholar
• Gazagne A, Claret E, Wijdenes J, et al. A fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J Immunol Methods. 2003;283(1–2):91–98.
   PubMed Web of Science ®Google Scholar
• Jung T, Schauer U, Heusser C, et al. Detection of intracellular cytokines by flow cytometry. J Immunol Methods. 1993;159:197–207.
   PubMed Web of Science ®Google Scholar
• Horton H, Thomas EP, Stucky JA, et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods. 2007 31;323(1):39–54.
   PubMed Web of Science ®Google Scholar
• Kiernan UA, Addobbati R, Nedelkov D, et al. Quantitative multiplexed C-reactive protein mass spectrometric immunoassay. J Proteome Res. 2006;5(7):1682–1687.
   PubMed Web of Science ®Google Scholar
• Khan SS, Smith MS, Reda D, et al. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom. 2004;61:35–39.
   PubMed Web of Science ®Google Scholar
• Tam SW, Wiese R, Lee S, et al. Simultaneous analysis of eight human Th1/Th2 cytokines using microarrays. J Immunol Methods. 2002;261:157–165.
   PubMed Web of Science ®Google Scholar
• Bjornson ZB, Nolan GP, Fantl WJ. Single-cell mass cytometry for analysis of immune system functional states. Curr Opin Immunol. 2013;25:484–494.
   PubMed Web of Science ®Google Scholar
• Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification and validation—Quality assurance and control of protein biomarker assays. Mol Oncol. 2014;8:840–858.
   PubMed Web of Science ®Google Scholar
• Grossmann J, Roschitzki B, Panse C, et al. “Implementation and evaluation of relative and absolute quantification in shotgun proteomics with label-freemethods,”. J Proteomics. 2010;73(9):1740–1746.
   PubMed Web of Science ®Google Scholar
• Trinh HV, Grossmann J, Gehrig P, et al. iTRAQ-based and label-free proteomics approaches for studies of human adenovirus infections. Int J Proteomics. 2013;2013:581862.
   PubMedGoogle Scholar
• Whiteaker JR. The increasing role of mass spectrometry in quantitative clinical proteomics. Clin Chem. 2010;56(9):1373–1374.
   PubMed Web of Science ®Google Scholar
• Ong SE, Blagoev B, Kratchmarova I, et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics. 2002;1(5):376–386.
   PubMed Web of Science ®Google Scholar
• Altelaar AF, Frese CK, Preisinger C, et al. Benchmarking stable isotope labeling based quantitative proteomics. J Proteomics. 2013 2;88:14–26.
   PubMed Web of Science ®Google Scholar
• Arntzen MO, Koehler CJ, Treumann A, et al. Quantitative proteome analysis using isobaric peptide termini labeling (IPTL). Methods Mol Biol. 2011;753:65–76.
   PubMedGoogle Scholar
• Latosinska A, Vougas K, Makridakis M, et al. Comparative analysis of label-free and 8-Plex iTRAQ approach for quantitative tissue proteomic analysis. PLoS ONE. 2015;10:e0137048.
   PubMedGoogle Scholar
• Chen TJ, Kotecha N. Cytobank: providing an analytics platform for community cytometry data analysis and collaboration. Curr Topics Microbiol Immunol. 2014;377:127–157.
   PubMed Web of Science ®Google Scholar
• Linderman MD, Bjornson Z, Simonds EF, et al. CytoSPADE: high-performance analysis and visualization of high dimensional cytometry data. Bioinformatics. 2012;28:2400–2401.
   PubMed Web of Science ®Google Scholar
• Kondo T, Ito F, Nakazawa H, et al. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol. 2004;171:2171–2175.
   PubMed Web of Science ®Google Scholar
• Gupta A, Mutebi M, Bardia A. Gene-expression-based predictors for breast cancer. Annals of Surgical Oncology. 2015;22(11):3418–3432.
   PubMed Web of Science ®Google Scholar
• Haukaas TH, Euceda LR, Giskeodegard GF, et al. Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. Cancer Metab. 2016;4:12.
   PubMed Web of Science ®Google Scholar
• Poddar S, Kesharwani D, Datta M. Interplay between the miRNome and the epigenetic machinery: implications in health and disease. J Cell Physiol. 2017;232:2938–2945.
   PubMed Web of Science ®Google Scholar
• Pearson WR, Wood T, Zhang Z, et al. Comparison of DNA sequences with protein sequences. Genomics. 1997;46(1):24–36.
   PubMed Web of Science ®Google Scholar
• Haque MM, Desai KV. Pathways to endocrine therapy resistance in breast cancer. Front Endocrinol. 2019;10:573.
   PubMed Web of Science ®Google Scholar
• Jurišić V, Obradovic J, Pavlović S. et al. Epidermal growth factor receptor gene in non-small-cell lung cancer: the importance of promoter polymorphism investigation. Anal Cell Pathol (Amst). 2018 14;2018:6192187. eCollection 2018.
   PubMedGoogle Scholar
• Jurisic V, Vukovic V, Obradovic J, et al. EGFR polymorphism and survival of NSCLC patients treated with TKIs: a systematic review and meta-analysis. J Oncol. 2020 18;2020:1973241.
   PubMed Web of Science ®Google Scholar
• Jurišić V, Obradović J, Tošić N, et al. Effects of DMSO, glycerol, betaine and their combinations in detecting single nucleotide polymorphisms of epidermal growth factor receptor (EGFR) gene promoter sequence in non-small-cell lung cancer (NSCLC) patients. J Pharm Biomed Anal. 2016 5;128:275–279.
   PubMed Web of Science ®Google Scholar
• Bogdanovic G, Jurisic V, Kraguljac N, et al. Characteristics of novel myeloid precursor cell line, PC-MDS, established from a bone marrow of the patient with therapy related myelodisplastic syndrome. Leuk Res. 2007;31:1105–1113.
   Web of Science ®Google Scholar
• Madorsky Rowdo FP, Barón A, Gallagher SJ, et al. Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition. Int J Oncol. 2020;56(6):1429–1441.
   PubMed Web of Science ®Google Scholar
• Nikolov S, Vera J, Schmitz U, et al. A model-based strategy to investigate the role of microRNA regulation in cancer signalling networks. Theory Biosci. 2011;130:55–69.
   PubMed Web of Science ®Google Scholar
• Kemp TJ, Moore JM, Griffith TS. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol. 2004;173:892–899.
   PubMed Web of Science ®Google Scholar
• Deb G, Thakur VS, Gupta S. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics. 2013;85:464–476. Epub 2013 Apr 17.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Li G, Podar K, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004 Apr 15;103(8):3158–3166.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Yamamoto K, Ioroi T, et al. Association of single nucleotide polymorphisms in STAT3, ABCB1, and ABCG2 with stomatitis in patients with metastatic renal cell carcinoma treated with sunitinib: a retrospective analysis in Japanese patients. Biol Pharm Bull. 2017;40(4):458–464.
   PubMed Web of Science ®Google Scholar
• McWhorter FY, Smith TD, Luu TU, et al. Macrophage secretion heterogeneity in engineered microenvironments revealed using a microwell platform. Integr Biol Quant Biosci Nano Macro. 2016;8:751–760.
   Google Scholar
• Kovarik P, Ebner F, Sedlyarov V. Posttranscriptional regulation of cytokine expression. Cytokine. 2017;89:21–26.
   PubMed Web of Science ®Google Scholar
• Ma C, Fan R, Ahmad H, et al. A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med. 2011;17:738–743.
   PubMed Web of Science ®Google Scholar
• Zelba H, Weide B, Martens A, et al. Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:4390–4399.
   PubMed Web of Science ®Google Scholar
• Mehta JP, Rani S. Software and tools for microarray data analysis. Methods Mol Biol. 2011;784:41–53.
   PubMedGoogle Scholar
• Clough E, Barrett T. The gene expression omnibus database. Methods Mol Biol. 2016;1418:93–111.
   PubMedGoogle Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543–550.
   PubMed Web of Science ®Google Scholar
• Smith RN, Aleksic J, Butano D, et al. InterMine: a flexible data warehouse system for the integration and analysis of heterogeneous biological data. Bioinformatics. 2020;28(23):3163–3165.
   Google Scholar
• Moorthy K, Jaber AN, Ismail MA, et al. Missing-values imputation algorithms for microarray gene expression data. In: Bolón-Canedo V, Alonso-Betanzos A, editors. Microarray bioinformatics. Methods in molecular biology. Vol. 1986. New York (NY): Humana; 2019. DOI:10.1007/978-1-4939-9442-7_12
   Google Scholar
• Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173(2):371–385; e318.
   Web of Science ®Google Scholar
• Garcıa V, Sanchez JS. Mapping microarray gene expression data into dissimilarity spaces for tumor classification. Inf Sci. 2015;294:362–375.
   Web of Science ®Google Scholar
• Moorthy K, Mohamad M, Deris S. A review on missing value imputation algorithms for microarray gene expression data. Curr Bioinform. 2014;9:18–22.
   Web of Science ®Google Scholar
• Perez De Souza L, Alseekh S, Brotman Y, et al. Network-based strategies in metabolomics data analysis and interpretation: from molecular networking to biological interpretation. Expert Rev Proteomics. 2020;17(4):243–255.
   PubMed Web of Science ®Google Scholar
• Clark DJ, Dhanasekaran SM, Petralia F, et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell. 2019;179:964–983.
   PubMed Web of Science ®Google Scholar
• Meier F, Geyer PE, Virreira Winter S, et al. BoxCar acquisition method enables single-shot proteomics at a depth of 10,000 proteins in 100 minutes. Nat Methods. 2018;15:440–448.
   PubMed Web of Science ®Google Scholar